Cutivate Lotion
Generic name:fluticasone propionate
Dosage form: topical lotion
Drug class:Topical steroids
Medically reviewed by Drugs.com. Last updated on Jul 22, 2021.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Cutivate Lotion
CUTIVATE® Lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 3 months of age or older.
Cutivate Lotion Dosage and Administration
Apply a thin film of CUTIVATE® Lotion to the affected skin areas once daily. Rub in gently.
Discontinue use when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
The safety and efficacy of CUTIVATE® Lotion have not been established beyond 4 weeks of use.
Avoid use with occlusive dressings or application to the diaper area [see Warnings and Precautions (5.1) and (5.2)].
CUTIVATE® Lotion is for topical use only, and not for ophthalmic, oral, or intravaginal use.
Dosage Forms and Strengths
Lotion, 0.05%. Each gram of CUTIVATE® Lotion USP contains 0.5 mg fluticasone propionate, USP in a white to off-white lotion base. CUTIVATE® Lotion USP is supplied in 120 mL bottles.
Contraindications
None.
Warnings and Precautions
Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Other Adverse Endocrine Effects
Topical corticosteroids, including CUTIVATE® Lotion, can produce reversible HPA axis suppression with the potential for glucocorticoid insufficiency. Risk factors that predispose to HPA axis suppression include the use of high-potency topical corticosteroids, large treatment surface areas, prolonged use, use under occlusion, concomitant use of more than one corticosteroid-containing product, altered skin barrier, and l...